EUVIMED · CrossrefJournal
ESMO Gastrointestinal Oncology
ISSN 2949-8198 · Elsevier BV
Latest articles
Early-onset pancreatic cancer: evidence for a distinct tumor subtype—a systematic review and meta-analysis
Comprehensive characterisation of patients with colorectal cancer and permanently liver-limited disease
Differences in treatment and outcomes between young and older patients with colorectal cancer liver metastases: an AmCORE-based study
Reprogramming the tumor microenvironment in MSS CRC: the role of TKIs in combination with immunotherapy
Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints
A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2 negative gastroesophageal adenocarcinomas
Early interim CT is the strongest prognostic factor in metastatic gastrointestinal neuroendocrine carcinomas (GI-NEC): results from the French NECTAR study
Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1–positive gastroesophageal adenocarcinoma—the IKF-t90/AIO/ZANGEA trial with translational analysis
Transarterial chemoembolization combined with immunotherapy-based treatments versus TACE alone in unresectable hepatocellular carcinoma: a systematic review and network meta-analysis
Transarterial chemoembolization (TACE) with or without immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis of randomized clinical trials
Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain
Rewriting the future of anal cancer care: From disparities to data-driven decisions
Table of Contents
Editorial Board
UCCL-IKF-AIO-STO-0124 NeoART—an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA)
Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study
Outcomes and management of primary tumors in metastatic MSI/dMMR colorectal cancer patients treated with immune checkpoint inhibitors: a cohort study
Immune checkpoint inhibitor-induced myocarditis with atrioventricular conduction abnormalities: a case report
Additional benefit of standardized computed tomography-based lymph node assessment utilizing Node-RADS in esophageal adenocarcinoma
ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy—phase II investigator-initiated trial (NCCH2412/MK015)
Preclinical identification and clinical validation of dynamic biomarkers for trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer
Real-world insights into young-onset gastroesophageal adenocarcinoma: an all-Ireland population-based cancer registry analysis
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study
Corrigendum to Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis
Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors
Dose optimization of immune checkpoint inhibitors for gastrointestinal malignancies
Checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer: treatment strategies, specificities, and care management questions
A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial
Table of Contents
EUVIMED